EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Factors Influencing Adherence to GLP-1 Receptor Agonist Therapy Among Patients Receiving Weight-Loss Injections

Rasha Salem Salama Alrehaili

Saudi Journal of Medicine and Public Health · 2026-07-10 · 3 (1) · 50-59

DOI: 10.64483/202631737 ↗

At a glance

Journal article in Saudi Journal of Medicine and Public Health, published online on 2026-07-10. Written by Rasha Salem Salama Alrehaili. The full text is freely available (open access, CC BY 4.0).

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of obesity and type 2 diabetes mellitus, with clinical trials demonstrating weight reductions exceeding 15% and significant cardiovascular benefits. However, a substantial and persistent gap exists between the efficacy observed in randomized controlled trials and the real-world effectiveness of these therapies, primarily driven by poor patient adherence and high discontinuation rates. This review synthesizes current evidence on the multifactorial determinants of GLP-1 RA adherence among patients using these medications for weight loss. Drawing upon real-world data from North America, Europe, Latin America, and Asia, we examine the physiological, psychological, economic, and healthcare system-related barriers that undermine treatment persistence. Gastrointestinal adverse effects, particularly nausea and vomiting, represent the most frequently cited physiological barrier, with discontinuation rates peaking during dose escalation. Economic barriers, including high out-of-pocket costs and inconsistent insurance coverage, profoundly impact adherence, with persistence falling below 10% in unsubsidized settings. Psychological factors, including the transient suppression of appetitive drive and the resurgence of "food noise" upon missed doses, further complicate long-term adherence. Healthcare system factors, including the quality of patient-provider communication, the provision of comprehensive education about dose titration and expected outcomes, and the availability of integrated nutritional and behavioral support, emerge as critical modifiable determinants of treatment persistence. This review proposes an integrated care framework incorporating medical nutrition therapy, structured lifestyle support, and patient-centered communication strategies to bridge the efficacy-effectiveness gap and optimize clinical outcomes in patients receiving GLP-1 RA therapy for weight management.

Cite

APA

Alrehaili, R. S. S. (2026). Factors Influencing Adherence to GLP-1 Receptor Agonist Therapy Among Patients Receiving Weight-Loss Injections. Saudi Journal of Medicine and Public Health, 3(1), 50-59. https://doi.org/10.64483/202631737

Vancouver

Alrehaili RSS. Factors Influencing Adherence to GLP-1 Receptor Agonist Therapy Among Patients Receiving Weight-Loss Injections. Saudi Journal of Medicine and Public Health. 2026;3(1):50-59. doi:10.64483/202631737

BibTeX
@article{Alrehaili2026,
  author = {Alrehaili, Rasha Salem Salama},
  title = {Factors Influencing Adherence to GLP-1 Receptor Agonist Therapy Among Patients Receiving Weight-Loss Injections},
  journal = {Saudi Journal of Medicine and Public Health},
  year = {2026},
  volume = {3},
  number = {1},
  pages = {50--59},
  doi = {10.64483/202631737}
}
Start for free →